Pyrilinks cleared for US:
This article was originally published in Clinica
Metra Biosystems' (US) Pyrilinks bone resorption tests have been cleared for US marketing by the FDA. The two urine-based assays (polyclonal and monoclonal) provide a quantitative measure of the excretion of pyridinium crosslinks as an indicator of type I collagen resorption. These assays join Alkphase-B, which measures serum levels of alkaline phosphatase, cleared in the US in August. Pyrilinks-D, which measures deoxypyridinoline, is pending FDA clearance.